Log in

OTCMKTS:ORGS - Orgenesis Stock Price, Forecast & News

-0.11 (-2.25 %)
(As of 02/19/2020 08:00 AM ET)
Today's Range
Now: $4.77
50-Day Range
MA: $4.94
52-Week Range
Now: $4.77
Volume19,000 shs
Average Volume65,238 shs
Market Capitalization$77.09 million
P/E RatioN/A
Dividend YieldN/A
Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:ORGS
Previous SymbolNASDAQ:ORGS



Sales & Book Value

Annual SalesN/A



Market Cap$77.09 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

Orgenesis (OTCMKTS:ORGS) Frequently Asked Questions

What is Orgenesis' stock symbol?

Orgenesis trades on the OTCMKTS under the ticker symbol "ORGS."

How were Orgenesis' earnings last quarter?

Orgenesis Inc (OTCMKTS:ORGS) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.26. The business earned $7.76 million during the quarter, compared to analyst estimates of $6.38 million. View Orgenesis' Earnings History.

What price target have analysts set for ORGS?

1 Wall Street analysts have issued twelve-month target prices for Orgenesis' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Orgenesis' stock price to reach $9.00 in the next year. This suggests a possible upside of 88.7% from the stock's current price. View Analyst Price Targets for Orgenesis.

What is the consensus analysts' recommendation for Orgenesis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orgenesis.

Has Orgenesis been receiving favorable news coverage?

Media headlines about ORGS stock have been trending negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Orgenesis earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Orgenesis.

What other stocks do shareholders of Orgenesis own?

Who are Orgenesis' key executives?

Orgenesis' management team includes the folowing people:
  • Vered Caplan, Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. (Age 46)
  • Neil T. Reithinger CPA, Chief Financial Officer, Treasurer, Secretary (Age 46)
  • Sarah Ferber Ph.D., Chief Scientific Officer (Age 60)
  • Yaron Adler, Director (Age 44)
  • Hugues Bultot, Director
  • David Sidransky M.D., Director (Age 57)
  • Guy Yachin, Director (Age 47)

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.09%). View Institutional Ownership Trends for Orgenesis.

Which institutional investors are buying Orgenesis stock?

ORGS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Orgenesis.

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $4.77.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $77.09 million. View Additional Information About Orgenesis.

What is Orgenesis' official website?

The official website for Orgenesis is http://www.orgenesis.com/.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480-659-6404 or via email at [email protected]

MarketBeat Community Rating for Orgenesis (OTCMKTS ORGS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe ORGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel